DE69838483D1 - Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten - Google Patents

Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten

Info

Publication number
DE69838483D1
DE69838483D1 DE69838483T DE69838483T DE69838483D1 DE 69838483 D1 DE69838483 D1 DE 69838483D1 DE 69838483 T DE69838483 T DE 69838483T DE 69838483 T DE69838483 T DE 69838483T DE 69838483 D1 DE69838483 D1 DE 69838483D1
Authority
DE
Germany
Prior art keywords
thymidine kinase
fusion proteins
mutations
guanylatekinase
mutanes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69838483T
Other languages
English (en)
Other versions
DE69838483T2 (de
Inventor
Margaret E Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Molecular Corp
Original Assignee
Darwin Molecular Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Darwin Molecular Corp filed Critical Darwin Molecular Corp
Application granted granted Critical
Publication of DE69838483D1 publication Critical patent/DE69838483D1/de
Publication of DE69838483T2 publication Critical patent/DE69838483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1229—Phosphotransferases with a phosphate group as acceptor (2.7.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
DE69838483T 1997-10-14 1998-10-14 Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten Expired - Lifetime DE69838483T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6181297P 1997-10-14 1997-10-14
US61812P 1997-10-14
PCT/US1998/021672 WO1999019466A2 (en) 1997-10-14 1998-10-14 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities

Publications (2)

Publication Number Publication Date
DE69838483D1 true DE69838483D1 (de) 2007-11-08
DE69838483T2 DE69838483T2 (de) 2008-07-03

Family

ID=22038301

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69838483T Expired - Lifetime DE69838483T2 (de) 1997-10-14 1998-10-14 Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten

Country Status (7)

Country Link
US (7) US7888091B2 (de)
EP (3) EP2386629A1 (de)
JP (3) JP2002516061A (de)
AT (1) ATE374247T1 (de)
CA (1) CA2306443A1 (de)
DE (1) DE69838483T2 (de)
WO (1) WO1999019466A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE374247T1 (de) * 1997-10-14 2007-10-15 Darwin Molecular Corp Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
GB0008966D0 (en) 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
AU783845B2 (en) * 2000-05-12 2005-12-15 Wolfgang Knecht Novel deoxynucleoside kinase enzyme variants
AU2001296864A1 (en) 2000-08-31 2002-03-13 Mayo Foundation For Medical Education And Research Detection of varicella-zoster virus
WO2002061390A2 (en) * 2001-01-31 2002-08-08 Mayo Foundation For Medical Education And Research Detection of herpes simplex virus
US7691571B2 (en) 2001-01-31 2010-04-06 Mayo Foundation For Medical Education And Research Detection of bordetella
US7439271B2 (en) * 2001-06-27 2008-10-21 The Gillette Company Reduction of hair growth
DK1509600T3 (da) 2002-05-23 2009-04-27 Wolfgang Knecht Plante thymidin kinaser og deres anvendelse
WO2003100045A1 (en) * 2002-05-23 2003-12-04 Wolfgang Knecht Plant thymidine kinases and their use
US7074598B2 (en) 2002-09-25 2006-07-11 Mayo Foundation For Medical Education And Research Detection of vancomycin-resistant enterococcus spp.
US7365176B2 (en) 2002-09-26 2008-04-29 Mayo Foundation For Medical Education And Research Detection of Epstein-Barr virus
US7074599B2 (en) 2002-09-27 2006-07-11 Mayo Foundation For Medical Education And Research Detection of mecA-containing Staphylococcus spp.
US7427475B2 (en) 2003-11-18 2008-09-23 Mayo Foundation For Medical Education And Research Detection of group B streptococcus
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
WO2013036526A1 (en) 2011-09-06 2013-03-14 Novozymes A/S Glucoamylase variants and polynucleotides encoding same
EP3988671A1 (de) * 2013-02-20 2022-04-27 Emory University Zusammensetzungen zur sequenzierung von nukleinsäuren in mischungen
AU2014236086B2 (en) 2013-03-14 2020-03-05 Genvivo, Inc. Improved thymidine kinase gene
US9951114B2 (en) 2013-06-04 2018-04-24 Virginia Commonwealth University Recombinant cancer therapeutic cytokine
WO2014197586A1 (en) 2013-06-04 2014-12-11 Virginia Commonwealth University Mda-9/syntenin promoter to image and treat metastatic cancer cells
US9750823B2 (en) 2013-06-04 2017-09-05 Virginia Commonwealth University Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics
US9454494B2 (en) * 2014-08-01 2016-09-27 Honeywell International Inc. Encrypting a communication from a device
WO2016100233A1 (en) 2014-12-15 2016-06-23 The Regents Of The University Of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
JP7099967B2 (ja) 2016-07-01 2022-07-12 リサーチ ディベロップメント ファウンデーション 幹細胞由来移植片からの増殖性細胞の排除
US11701384B2 (en) 2016-09-02 2023-07-18 The Regents Of The University Of California Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
US11542524B2 (en) * 2017-11-29 2023-01-03 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
CA3129883A1 (en) * 2019-02-14 2020-08-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CN109735571A (zh) * 2019-03-11 2019-05-10 四川药智联恒科技有限公司 双自杀基因慢病毒表达载体及其应用
US20230265457A1 (en) * 2021-10-25 2023-08-24 Genvivo, Inc. Compositions and methods for therapeutic delivery

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018884A (en) 1975-06-26 1977-04-19 Hoffmann-La Roche Inc. Fluorogenic materials and labeling techniques
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4514497B1 (en) 1983-12-30 1998-02-24 Novagene Inc Modified live pseudorabies viruses
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4801542A (en) 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4744981A (en) 1985-10-17 1988-05-17 Neorx Corporation Trichothecene antibody conjugates
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4851341A (en) 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
EP0329184A3 (de) 1988-02-19 1990-05-23 Neorx Corporation Antimere und antimere Konjugation
US4988496A (en) 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
GB8914543D0 (en) 1989-06-23 1989-08-09 Parker David Chemical compounds
EP0487587A1 (de) 1989-08-18 1992-06-03 Chiron Corporation Rekombinante retroviren um vektorkonstruktionen an zielzellen zu liefern
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
SE9003978D0 (sv) 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US5203975A (en) 1991-10-29 1993-04-20 E. I. Du Pont De Nemours And Company Process for cathodic electrodeposition of a clear coating over a conductive paint layer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
EP0644946A4 (de) 1992-06-10 1997-03-12 Us Health Gegen die inaktivierung durch menschliches serum resistente vektorpartikel.
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
ATE232238T1 (de) 1992-12-23 2003-02-15 Arch Dev Corp Synthetische promotoren von herpes simplex virus
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
CA2167706A1 (en) 1993-07-27 1995-02-09 Nigel Fraser Modified dna virus vectors and uses therefor
EP0716148B1 (de) 1993-09-15 2004-01-02 Chiron Corporation Rekombinanter Alphavirus Vektor
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
EP0758387B1 (de) 1994-05-02 2001-12-19 University of Washington Thymidin-kinase-mutanten
FR2723962B1 (fr) * 1994-08-25 1996-10-31 Univ Paris Curie Hsv1-tk modifiee fonctionnelle
JP2000505288A (ja) * 1996-02-09 2000-05-09 ローヌ―プーラン・ロレ・エス・アー チミジンキナーゼ変異体、対応する核酸配列および遺伝子治療におけるそれらの用途
FR2746016B1 (fr) * 1996-03-15 1998-04-17 Combinaisons d'enzymes pour la destruction de cellules proliferatives
ATE374247T1 (de) * 1997-10-14 2007-10-15 Darwin Molecular Corp Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten

Also Published As

Publication number Publication date
DE69838483T2 (de) 2008-07-03
WO1999019466A2 (en) 1999-04-22
EP1025212B1 (de) 2007-09-26
JP2008301828A (ja) 2008-12-18
US20130011903A1 (en) 2013-01-10
US8163528B2 (en) 2012-04-24
EP2386630A1 (de) 2011-11-16
US20090298156A1 (en) 2009-12-03
US20120149890A1 (en) 2012-06-14
US20100112685A1 (en) 2010-05-06
US8236541B2 (en) 2012-08-07
JP5070145B2 (ja) 2012-11-07
US20110165653A1 (en) 2011-07-07
CA2306443A1 (en) 1999-04-22
US7888114B2 (en) 2011-02-15
EP1025212A2 (de) 2000-08-09
JP2002516061A (ja) 2002-06-04
US7888091B2 (en) 2011-02-15
WO1999019466A3 (en) 1999-07-08
JP2012115270A (ja) 2012-06-21
US20110136221A1 (en) 2011-06-09
ATE374247T1 (de) 2007-10-15
US20120142071A1 (en) 2012-06-07
EP2386629A1 (de) 2011-11-16

Similar Documents

Publication Publication Date Title
DE69838483D1 (de) Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
ATE211174T1 (de) Thymidin-kinase-mutanten
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
DE69840361D1 (de) Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
BR9913360B1 (pt) proteÍna de uricase recombinante quimÉrica, molÉcula de Ácido nuclÉico isolada e purificada, vetor e cÉlula hospedeira transformada.
ATE503843T1 (de) Gesamt-chromosom analyse von protein-dns wechselwirkungen
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
DK1137812T3 (da) DNA-proteinfusioner og anvendelser deraf
ATE304052T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
EP1012603A4 (de) Funktionelle fragmente des hiv-1 vpr proteins and eine methode zu seiner anwendung
ATE277171T1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
CA2281955A1 (en) Ikb kinase, subunits thereof, and methods of using same
WO2003016551A3 (en) Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
BR9806183A (pt) Quinases de proteìna e usos das mesmas
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
WO2000017346A3 (en) Hairpin hybridizer molecules for modulation of gene expression
WO2003012103A3 (fr) Acides nucleiques codant de nouvelles proteines a boite f, leurs utilisations en diagnostic et en therapie
AP9901510A0 (en) Polypeptides comprising gax protein domains, involved in repressing transcription and or interacting with other proteins corresponding nucleic acids andtheir use.
WO2003012102A3 (fr) Acides nucleiques codant des proteines a domaine hect
WO2002059149A3 (en) Pro-apoptotic proteins and dna molecules encoding them
WO2002034899A3 (en) Tec kinase assay
DK1064389T3 (da) Sammensætninger med fusionsproteiner af kinase Wee1, nukleotidsekvenser, ekspressionssystemer og fremgangsmåder til deres anvendelse
DE69941299D1 (de) Zusammensetzungen und verfahren zur behandlung der polyzystischen nierenkrankheit
ATE329046T1 (de) Parvovirus-vektoren und deren verwendung

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition